

STW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Mark A. Dombroski, et al.	Examiner:	Evelyn Mei Huang
Serial No:	10/649,255	Art Unit:	1625
Filed:	August 27, 2003	Docket:	17569 (PC23304A)
For:	CYCLOALKYL- [4-(DIFLUOROPHENYL) -OXAZOL-5-YL]-TRIAZOLO- PYRIDINES	Dated:	July 11, 2005

Confirmation No.: 5909

Mail Stop Duplicates
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE UNDER 37 C.F.R. §1.251-PENDING APPLICATION


Sir:

Applicants herein make available to the United States Patent and Trademark Office a copy of the PTO-FB-A820 form, which was previously filed on August 27, 2003, for the above-referenced patent application. Also enclosed are copies of the references (except U.S. Patent documents) cited by the Applicants in PTO-FB-A820 form.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Duplicates, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 11, 2005



Peter I. Bernstein

Applicants submit that the enclosed Information Disclosure Statement filed August 27, 2003 and associated references is a complete and accurate copy of applicant's record of such papers.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Applicants submit the following response for entry in the above-identified case.


Respectfully submitted,



Peter I. Bernstein
Registration No. 43,497

Scully, Scott, Murphy & Presser
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB/RLB:dg



COMMISSIONER FOR PATENTS

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

In re Application of: DOMBROSKI, MARK A. et al
Application No.: 10/649255
Filing Date: 08/27/03
Title: CYCLOALKYL-[4-(DIFLUOROPHENYL)-OXAZOL-5-YL]-TRIAZOLO-PYRIDINES
Direct to: U. S. Patent and Trademark Office
Mail Stop: Duplicates
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

NOTICE UNDER 37 CFR 1.251 — Pending Application

Statement (check the appropriate box):


☒ The copy submitted with this reply is a complete and accurate copy of applicant's record of all of the correspondence between the Office and the applicant for the above-identified application (except for U.S. patent documents); and applicant is not aware of any correspondence between the Office and applicant for the above-identified application that is not among applicant's records.

☐ The copy of the paper(s) listed in the notice under 37 CFR 1.251 is/are a complete and accurate copy of applicant's record of such paper(s).

☐ The papers produced by applicant are applicant's complete record of all of the correspondence between the Office and the applicant for the above-identified application (except for U.S. patent documents), and applicant is not aware of any correspondence between the Office and the applicant for the above-identified application that is not among applicant's records.

☐ Applicant does not possess any record of the correspondence between the Office and the applicant for the above identified application.

July 11, 2005
Date


Signature

Peter I. Bernstein
Typed or printed name

A Copy of this notice should be returned with the reply.

Burden Hour Statement: This collection of information is required by 37 CFR 1.251. The information is used by the public to reply to a request for copies of correspondence between the applicant and the USPTO in order to reconstruct an application file. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 60 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.



Patent Application
Attorney Docket No.: PC23304A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **DOMBROSKI, ET AL.** :

APPLICATION NO.: **NOT YET ASSIGNED** : Examiner: **NOT ASSIGNED**

FILING DATE: **HEREWITH** : Group Art Unit: **NOT ASSIGNED**

TITLE: **CYCLOALKYL-[4** :
(DIFLUOROPHENYL)-OXAZOL-5- :
YL]-TRIAZOLO-PYRIDINES :

Mail Stop PATENT APPLICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.


Respectfully submitted,

Date:

August 27, 2003

Garth Butterfield
GARTH BUTTERFIELD
Attorney for Applicants
Reg. No. 36,997

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 573-1229



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC23304A				SERIAL NO. NOT ASSIGNED								
		APPLICANT DOMBROSKI, ET AL.												
		FILING DATE HEREWITH				GROUP NOT ASSIGNED								
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5	7	1	6	9	5	5	2/10/98	ADAMS, ET AL.	514	235.8		
		5	7	1	6	9	7	2	2/10/98	ADAMS, ET AL.	514	341		
		5	7	1	7	1	0	0	2/10/98	SELNICK, ET AL.	546	194		
		5	7	5	6	4	9	9	5/26/98	ADAMS, ET AL.	514	235.8		
		5	7	7	7	0	9	7	7/7/98	LEE, ET AL.	536	24.31		
		6	2	8	8	0	6	2	9/11/01	ADAMS, ET AL.	514	236.8		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
		9	9	0	1	4	4	9	1/14/99	PCT	C07D	401/04		
		9	9	6	1	4	4	0	12/2/99	PCT	C07D	403/14		
		0	0	0	6	5	6	3	2/10/00	PCT	C07D	401/04		
		0	0	3	1	0	6	5	6/2/00	PCT	C07D	401/04		
		0	0	3	5	9	1	1	6/22/00	PCT	C07D	405/14		
		0	0	4	0	2	4	3	7/13/00	PCT	A61K	31/444		
		0	0	4	1	6	9	8	7/20/00	PCT	A61K	31/535		
		0	0	6	3	2	0	4	10/26/00	PCT	C07D	413/00		
		0	2	7	2	5	7	6	9/19/02	PCT	C07D	403/14		
		0	2	7	2	5	7	9	9/19/02	PCT	C07D	471/04		
		1	2	4	7	8	1	0	10/9/02	EP	C07D	403/04		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		The Journal of Biological Chemistry, Vol. 271, No. 40, pp. 24313-24316 (1996);												
		Bioorganic & Medicinal Chemistry Letters, 10, pp. 2047-2050 (2000); and												
		Bioorganic & Medicinal Chemistry Letters, 11, pp. 9-12 (2001).												
EXAMINER		DATE CONSIDERED												
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE CITATION LIST.DOT, 3/99

EXPRESS MAIL NO.: EL 639816799 US

USERS\DOCS\LA21952\LPGXB\HTT011.DOC / 209729